MAMORU HARADA

Prof. MAMORU HARADA


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2012 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MTMiki Tongu
Miki Tongu
NHNanae Harashima
Nanae Harashima
HMHiroyuki Monma
Hiroyuki Monma
TITouko Inao
Touko Inao
TYTakaya Yamada
Takaya Yamada
MHMAMORU HARADA
MAMORU HARADA

29 October 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
NHNanae Harashima
Nanae Harashima
TITohko Inao
Tohko Inao
RIRyu Imamura
Ryu Imamura
SOShinji Okano
Shinji Okano
TSTakashi Suda
Takashi Suda
MHMAMORU HARADA
MAMORU HARADA

22 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
TITouko Inao
Touko Inao
YIYuichi Iida
Yuichi Iida
TMTamami Moritani
Tamami Moritani
TOTamio Okimoto
Tamio Okimoto
RTRyosuke Tanino
Ryosuke Tanino
MHMAMORU HARADA
MAMORU HARADA
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin

15 October 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
HTHiroki Tamaki
Hiroki Tamaki
NHNanae Harashima
Nanae Harashima
MHMiho Hiraki
Miho Hiraki
NANaoko Arichi
Naoko Arichi
NNNobuhiro Nishimura
Nobuhiro Nishimura
MHMAMORU HARADA
MAMORU HARADA
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition

22 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MZMin Zhang
Min Zhang
NHNanae Harashima
Nanae Harashima
TMTamami Moritani
Tamami Moritani
WHWeidong Huang
Weidong Huang
MHMAMORU HARADA
MAMORU HARADA
Death signaling provided by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) can induce death in cancer cells with little cytotoxicity to normal cells; this cell death has been thought to involve caspase-dependent apoptosis. Reactive oxygen species (ROS) are also mediators that induce cell death, but their roles in TRAIL-induced apoptosis have not been elucidated fully. In the current study, we investigated ROS and caspases in human pancreatic cancer cells undergoing two different types of TRAIL-induced cell death, apoptosis and necroptosis. TRAIL treatment increased ROS in two TRAIL-sensitive pancreatic cancer cell lines, MiaPaCa-2 and BxPC-3, but ROS were involved in TRAIL-induced apoptosis only in MiaPaCa-2 cells. Unexpectedly, inhibition of ROS by either N-acetyl-L-cysteine (NAC), a peroxide inhibitor, or Tempol, a superoxide inhibitor, increased the annexin V-/propidium iodide (PI)+ early necrotic population in TRAIL-treated cells. Additionally, both necrostatin-1, an inhibitor of receptor-interacting protein kinase 1 (RIP1), and siRNA-mediated knockdown of RIP3 decreased the annexin V-/PI+ early necrotic population after TRAIL treatment. Furthermore, an increase in early apoptosis was induced in TRAIL-treated cancer cells under inhibition of either caspase-2 or -9. Caspase-2 worked upstream of caspase-9, and no crosstalk was observed between ROS and caspase-2/-9 in TRAIL-treated cells. Together, these results indicate that ROS contribute to TRAIL-induced apoptosis in MiaPaCa-2 cells, and that ROS play an inhibitory role in TRAIL-induced necroptosis of MiaPaCa-2 and BxPC-3 cells, with caspase-2 and -9 playing regulatory roles in this process.

19 May 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
YSYusuke Satoh
Yusuke Satoh
HKHitoshi Kotani
Hitoshi Kotani
YIYuichi Iida
Yuichi Iida
TTTakahito Taniura
Takahito Taniura
YNYoshitomo Notsu
Yoshitomo Notsu
MHMAMORU HARADA
MAMORU HARADA
Myeloid‐derived suppressor cells (MDSCs) play a crucial role in immunosuppression in tumor‐bearing hosts. MDSCs express arginase‐I and indoleamine 2,3‐dioxygenase; they suppress T‐cell function by reducing the levels of l‐arginine and l‐tryptophan, respectively. We examined the anticancer effects of supplementation of these amino acids in CT26 colon carcinoma‐bearing mice. Oral supplementation of l‐arginine or l‐tryptophan (30 mg/mouse) did not affect tumor growth, whereas oral supplementation of d‐arginine was lethal. Supplementation of l‐arginine showed a tendency to augment the efficacy of cyclophosphamide (CP). CP reduced the proportions of granulocytic MDSCs and increased the proportions of monocytic MDSCs in the spleen and tumor tissues of CT26‐bearing mice. l‐Arginine supplementation alone did not affect the MDSC subsets. CP treatment tended to reduce the plasma levels of l‐arginine in CT26‐bearing mice and significantly increased the number of tumor‐infiltrating CD8+ T cells. In addition, l‐arginine supplementation significantly increased the proportions of tumor peptide‐specific CD8+ T cells in draining lymph nodes. Importantly, additional supplementation of l‐arginine significantly increased the number of cured mice that were treated with CP and anti‐PD‐1 antibody. Totally, l‐arginine supplementation shows promise for boosting the therapeutic efficacy of chemoimmunotherapy.